Clinical Trial Update: BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 trial assessing risankizumab versus placebo in Japanese patients with moderate to severe chronic plaque psoriasis; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Risankizumab (risankizumab)

Snippet

Sponsor: AbbVie | Conditions: Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2019-02-06